#

19-21 SEPTEMBER 2017 //

MARITIM PROARTE HOTEL, BERLIN

Register Now

Enquiry

Speakers

Loading
Jason Slingsby

Jason Slingsby

Head of Business Development, Oxford Biomedica

Jason is Head of Business Development at Oxford BioMedica plc. He was awarded a first class degree in Biochemistry from Magdalen College, Oxford University and has a PhD in disease genetics from Imperial College London. He was also awarded an MBA with distinction from London Business School. Jason has been involved in gene therapy since 1997, when he first joined Oxford BioMedica as a post-doc. Since then, he has held a number of business development roles including at Sosei Co. Ltd. and Intercell AG. From 2005 to 2012, he was founder and CEO of ProtAffin AG, a clinical-stage biologics platform company, financed by VCs including Atlas Venture, SR One and Aescap.

Sessions

2017 Speakers

"It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance."

Bertrand Alexandre, Director, Marketing Europe, Celyad

Sponsors

  • #
  • #
  • #
  • #
  • TrakCel, Silver Sponsor at Cell & Gene Therapy Europe
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #